Patents by Inventor Chris Allan Veale

Chris Allan Veale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6939896
    Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: September 6, 2005
    Assignee: AstraZeneca AB
    Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Publication number: 20040204390
    Abstract: The present invention relates to a pharmaceutical product or daily dose comprising an anti-androgen, an oestrogen receptor &bgr; (ER&bgr;) selective agonist and optionally a chemical castration agent. The invention also relates to a method of therapeutically treating and/or preventing an androgen-stimulated disease (eg, prostate cancer or benign prostate hypertrophy) in a patient. Furthermore, the invention relates to the use of an anti-androgen, an ER&bgr; selective agonist and optionally a chemical castration agent in the manufacture of a pharmaceutical product for this purpose.
    Type: Application
    Filed: May 26, 2004
    Publication date: October 14, 2004
    Inventors: Barrington John Albert Furr, Anthony Nigel Brooks, Chris Allan Veale
  • Publication number: 20030207812
    Abstract: Substituted phenanthrene-9,10-diones in accord with structural diagram I, 1
    Type: Application
    Filed: November 25, 2002
    Publication date: November 6, 2003
    Inventors: Marc Jerome Chapdelaine, Katharine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Publication number: 20030130298
    Abstract: Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.
    Type: Application
    Filed: November 25, 2002
    Publication date: July 10, 2003
    Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Publication number: 20030119897
    Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 26, 2003
    Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
  • Patent number: 6054593
    Abstract: The present invention relates to particular forms of a novel 1-substituted-N-[2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: April 25, 2000
    Assignee: Zeneca Limited
    Inventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies
  • Patent number: 6048889
    Abstract: The present invention relates to particular forms of a novel 1-substituted-N-[2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: April 11, 2000
    Assignee: Zeneca Limited
    Inventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies
  • Patent number: 6037363
    Abstract: The present invention relates to pyrrolidine derivative compounds, and more particularly to the compound (S)-1-[(S)-2-(4-methoxybenzamido)-3-methylbutyryl]-N-[(S)-2-methyl-1-(trif luoroacetyl)propyl]pyrrolidine-2-carboxamide, shown by the formula I, a pharmaceutical composition comprising this compound in a crystalline form and a process for preparing the pharmaceutical composition. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: March 14, 2000
    Assignee: Zeneca Limited
    Inventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
  • Patent number: 5965576
    Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: October 12, 1999
    Assignee: Zeneca Limited
    Inventors: Ashokkumar Bhikkappa Shenvi, Robert Toms Jacobs, Scott Carson Miller, Cyrus John Ohnmacht, Jr., Chris Allan Veale
  • Patent number: 5907043
    Abstract: The present invention relates to pyrrolidine derivatives, and more particularly to the compound (S)-1-?(S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N-?(S)-2-methyl-1-(trif luoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by formula I, and solvates thereof. The present invention also provides pharmaceutical compositions, intermediates and methods of preparation of the compound. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: May 25, 1999
    Assignee: Zeneca Limited
    Inventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
  • Patent number: 5808097
    Abstract: The present invention relates to particular forms of a novel 1-substituted-N-?2-methyl-1-(trifluoroacetyl)propyl!pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: September 15, 1998
    Assignee: Zeneca Limited
    Inventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies
  • Patent number: 5739149
    Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    Type: Grant
    Filed: February 3, 1997
    Date of Patent: April 14, 1998
    Assignee: Zeneca Limited
    Inventors: Robert Toms Jacobs, Scott Carson Miller, Ashokkumar Bhikkappa Shenvi, Cyrus John Ohnmacht, Jr., Chris Allan Veale
  • Patent number: 5739157
    Abstract: The present invention relates to pyrrolidine derivatives, and more particularly to the compound (S)-1-?(S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N-?(S)-2-methyl-1-(trif luoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by formula I, and solvates thereof. The present invention also provides pharmaceutical compositions, intermediates and methods of preparation of the compound. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: April 14, 1998
    Assignee: Zeneca Limited
    Inventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
  • Patent number: 5736535
    Abstract: The present invention relates to certain novel substituted derivatives which are 1-pyrimidinylacetamide derivatives of formula I, ##STR1## which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these substituted derivatives, processes for preparing the substituted derivatives, pharmaceutical compositions containing such substituted derivatives and methods for their use.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: April 7, 1998
    Assignee: Zeneca Limited
    Inventors: Peter Robert Bernstein, Philip Duke Edwards, Andrew Shaw, Ashokkumar Bhikkappa Shenvi, Royston Martin Thomas, Chris Allan Veale, Peter Warner, Donald John Wolanin
  • Patent number: 5721222
    Abstract: The present invention relates to certain novel heterocyclic ketones which are 1-pyridylacetamide ketones of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic ketones, processes for preparing the heterocyclic ketones, pharmaceutical compositions containing such heterocyclic ketones and methods for their use.
    Type: Grant
    Filed: August 25, 1995
    Date of Patent: February 24, 1998
    Assignee: ZENECA Limited
    Inventors: Peter Robert Bernstein, Andrew Shaw, Royston Martin Thomas, Chris Allan Veale, Peter Warner, Donald John Wolanin
  • Patent number: 5705505
    Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: January 6, 1998
    Assignee: Zeneca Limited
    Inventors: Ashokkumar Bhikkappa Shenvi, Robert Toms Jacobs, Scott Carson Miller, Cyrus John Ohnmacht, Jr., Chris Allan Veale
  • Patent number: 5686628
    Abstract: The present invention relates to particular forms of a novel 1-substituted-N-?2-methyl-1-(trifluoroacetyl)propyl!pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: November 11, 1997
    Assignee: Zeneca Ltd.
    Inventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies